This indicates that Oncotype Dx may serve as a guide in predicting the utility of chemotherapy in patients with carcinomas that are ER+ with ITCs, since the biological potential of the latter is uncertain [27, 28]. This evidence concerns the gene ESR1 and carcinoma.